studies

mML - L1 - all population, ... vs. nivolumab alone, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.59 [1.22; 2.06] 1.59[1.22; 2.06]CheckMate 067 (N vs I ; all population), 2015 (REV)10%631NAnot evaluable deaths (OS) (extension)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.59 [1.31; 1.92] 1.59[1.31; 1.92]CheckMate 067 (N vs I ; all population), 2015 (REV)10%631NAnot evaluable PFS (extension)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.89 [1.56; 2.28] 1.89[1.56; 2.28]CheckMate 067 (N vs I ; all population), 2015 (REV)10%631NAnot evaluable progression or deaths (PFS)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.75 [1.32; 2.33] 1.75[1.32; 2.33]CheckMate 067 (N vs I ; all population), 2015 (REV)10%631NAnot evaluable objective responses (ORR)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.29 [0.17; 0.49] 0.29[0.17; 0.49]CheckMate 067 (N vs I ; all population), 2015 (REV)10%631NAnot evaluable objective responses (ORR) (extension)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.28 [0.20; 0.41] 0.28[0.20; 0.41]CheckMate 067 (N vs I ; all population), 2015 (REV)10%631NAnot evaluable TRAE (any grade)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.99 [0.63; 1.56] 0.99[0.63; 1.56]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.40 [0.97; 2.03] 1.40[0.97; 2.03]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] 1.01[0.02; 50.88]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.40 [0.88; 2.21] 1.40[0.88; 2.21]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.93 [1.14; 3.27] 1.93[1.14; 3.27]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 4.05 [0.18; 90.07] 4.05[0.18; 90.07]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56] 0.50[0.05; 5.56]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03] 0.50[0.02; 15.03]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39] 2.02[0.18; 22.39]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 8.64 [2.57; 29.01] 8.64[2.57; 29.01]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Cough TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.25 [0.01; 5.58] 0.25[0.01; 5.58]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 2.08 [0.92; 4.69] 2.08[0.92; 4.69]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Dry skin TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] 1.01[0.02; 50.88]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03] 0.50[0.02; 15.03]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.20; 5.03] 1.01[0.20; 5.03]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Headache TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] 1.01[0.02; 50.88]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] 1.01[0.02; 50.88]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 5.10 [0.59; 43.89] 5.10[0.59; 43.89]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] 1.01[0.02; 50.88]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.67 [0.11; 4.03] 0.67[0.11; 4.03]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.26 [0.34; 4.75] 1.26[0.34; 4.75]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.86 [0.39; 1.88] 0.86[0.39; 1.88]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56] 0.50[0.05; 5.56]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03] 0.50[0.02; 15.03]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 4.05 [0.18; 90.07] 4.05[0.18; 90.07]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16] 1.01[0.06; 16.16]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] 1.01[0.02; 50.88]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16] 1.01[0.06; 16.16]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 5.10 [0.59; 43.89] 5.10[0.59; 43.89]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] 1.01[0.02; 50.88]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Vitiligo TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03] 0.50[0.02; 15.03]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16] 1.01[0.06; 16.16]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsCheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CheckMate 067 (N vs I ; all population), 2015 (REV)10%624NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-07-05 10:45 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 68 - treatments: 329

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons